2026 FDA Drug Approvals Relevant to PI: Attorney Update

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 7 min read

Several 2026 FDA drug approvals directly impact personal injury pharmacy practice, including Journavx for acute pain, Tonmya for fibromyalgia, and emerging biologics for chronic pain conditions. This attorney update covers what PI practitioners need to know about new medications entering the lien pharmacy landscape.

The FDA's 2025-2026 approval cycle has produced several new medications directly relevant to personal injury pharmacy, led by Journavx (suzetrigine) — the first non-opioid NaV1.8 inhibitor for acute pain — and Tonmya (cyclobenzaprine sublingual) for fibromyalgia. These approvals change the treatment landscape for PI patients and create new documentation opportunities that attorneys should understand because new drug classes entering the pharmacy record carry outsized evidentiary weight in settlement negotiations.

• Journavx (suzetrigine), approved January 2025, is the first selective NaV1.8 sodium channel inhibitor for moderate-to-severe acute pain — a non-opioid mechanism that fundamentally changes post-surgical and post-injury pain management (FDA Approval Letter, January 30, 2025)
• Tonmya (TNX-102 SL, cyclobenzaprine sublingual), approved in 2025 for fibromyalgia, is the first FDA-approved treatment specifically for fibromyalgia using sublingual cyclobenzaprine — relevant for post-traumatic fibromyalgia cases
• LienScripts covers newly approved medications on pharmacy lien as they enter clinical use, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that identifies novel drug classes in the treatment record
• According to James Wong, PharmD, founder of LienScripts, "New FDA approvals create a documentation advantage for early adopters — when a prescriber uses a newly approved mechanism like Journavx instead of an opioid, it demonstrates cutting-edge pain management that is harder for defense to challenge"
• Emerging pipeline drugs for chronic pain, neuropathy, and inflammation will continue reshaping PI pharmacy through 2026-2027

Journavx (Suzetrigine) — Non-Opioid Acute Pain

What It Is

Journavx is a selective inhibitor of the NaV1.8 sodium channel — a channel expressed primarily on peripheral pain-sensing neurons (nociceptors). By blocking NaV1.8, suzetrigine reduces pain signal transmission without affecting the central nervous system reward pathways that cause opioid dependence and abuse (Vertex Pharmaceuticals; FDA approval January 30, 2025).

FDA Approval

Approved for moderate-to-severe acute pain in adults. The ALTITUDE trials demonstrated non-inferiority to hydrocodone/acetaminophen for post-surgical pain (abdominoplasty and bunionectomy models) with significantly fewer CNS side effects.

PI Implications

For personal injury attorneys, Journavx in the pharmacy record documents:

1. Modern pain management — the prescriber is using the newest mechanism-based therapy, not defaulting to opioids
2. Pain severity — Journavx is indicated for moderate-to-severe pain, not mild discomfort
3. Standard-of-care evolution — as non-opioid options become available, their prescription demonstrates the injury required prescription-level pain management while the provider actively avoided opioid risk

[!KEY] Journavx represents a paradigm shift: the first time prescribers can treat moderate-to-severe acute pain with a mechanism as effective as opioids but without opioid risks. Its presence in the pharmacy record documents acute pain severity while simultaneously showing the prescriber chose the safest effective option — a narrative that resonates with juries and adjusters.

Cost and Lien Coverage

Journavx is a branded medication with no generic equivalent. LienScripts covers Journavx on pharmacy lien when prescribed for PI-related pain conditions.

Tonmya (Cyclobenzaprine Sublingual) — Fibromyalgia

What It Is

Tonmya is a sublingual formulation of cyclobenzaprine — a well-known muscle relaxant — reformulated at a low dose (2.8mg or 5.6mg sublingual, taken at bedtime) specifically for fibromyalgia. The sublingual route provides different pharmacokinetics than oral cyclobenzaprine, with lower peak levels and a profile optimized for sleep architecture improvement and central pain modulation.

FDA Approval

Tonmya received FDA approval for fibromyalgia management. The RESILIENCE trial demonstrated significant improvement in fibromyalgia pain and sleep quality compared to placebo (Tonix Pharmaceuticals).

PI Implications

Post-traumatic fibromyalgia — fibromyalgia triggered by physical trauma such as a car accident — is a well-recognized condition (Buskila et al., Arthritis & Rheumatism, 1997). Before Tonmya, there were only three FDA-approved fibromyalgia drugs (duloxetine, milnacipran, pregabalin), and none were specifically developed for the condition.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Tonmya is the first drug purpose-built for fibromyalgia in over a decade. When a prescriber uses Tonmya for a post-traumatic fibromyalgia patient, that prescription documents a specific fibromyalgia diagnosis treated with a fibromyalgia-specific medication — not an off-label repurpose."

[!TIP] If your client has been diagnosed with post-traumatic fibromyalgia, ask the treating provider about Tonmya. A fibromyalgia-specific medication strengthens the diagnostic documentation compared to off-label use of duloxetine or pregabalin, which have multiple indications.

Emerging Pipeline Drugs for PI-Relevant Conditions

Anti-CGRP Agents — Expanding Indications

The CGRP antagonist class continues to expand. Atogepant (Qulipta) received an expanded indication for chronic migraine prevention in 2024, and clinical trials are exploring CGRP agents for post-traumatic headache specifically. An FDA-approved indication for post-traumatic headache — rather than just "migraine" — would strengthen the causation argument in PI cases.

NaV1.7 and NaV1.8 Inhibitors — Next-Generation Pain

Following Journavx's approval, additional NaV channel inhibitors are in development for chronic pain conditions including neuropathic pain and osteoarthritis. These represent the next generation of non-opioid pain medications with potential applications in long-term PI pain management.

Nerve Growth Factor (NGF) Inhibitors

Tanezumab and fasinumab (anti-NGF monoclonal antibodies) have been in development for chronic pain. While tanezumab's FDA application was withdrawn, the NGF pathway remains a target for chronic musculoskeletal pain that could eventually produce approved therapies for PI-relevant conditions.

Resiniferatoxin — Targeted Nerve Ablation

Resiniferatoxin, a TRPV1 agonist that selectively destroys pain-sensing nerve fibers, is in clinical trials for intractable pain. If approved, it would represent a fundamentally new approach to chronic pain management with significant PI implications.

[!KEY] The 2025-2026 FDA approval cycle is the most significant for PI-relevant pain medications in over a decade. Journavx provides the first non-opioid option for moderate-to-severe acute pain, Tonmya adds the first purpose-built fibromyalgia treatment in years, and the pipeline suggests more novel mechanisms are coming.

What Attorneys Should Do Now

1. Stay Current on New Medications

New drug approvals create early documentation advantages. The first patients treated with Journavx or Tonmya will have pharmacy records showing cutting-edge, mechanism-specific therapy that defense experts cannot dismiss as routine.

2. Discuss New Options with Treating Providers

If your client's pain condition might benefit from a newly approved medication, coordinate with the treating provider. Early adoption of Journavx for post-surgical pain or Tonmya for post-traumatic fibromyalgia strengthens the treatment record.

3. Ensure Lien Coverage

LienScripts covers newly approved medications on pharmacy lien as they enter clinical use. A MERIT (Medication Evaluation & Rationale for Injury Treatment) report identifies novel drug classes and explains their clinical significance in the demand package context.

4. Understand the Cost Structure

Newly approved, branded medications carry premium pricing with no generic alternatives. This is not a prescriber choice — it is the only available formulation. Defense arguments about "cheaper alternatives" fail when the medication class has no generic equivalent.

Frequently Asked Questions

For lien-based coverage of newly approved medications including Journavx and Tonmya, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• Journavx for Acute Fracture Pain on Pharmacy Lien
• Journavx for Post-Surgical Pain and Settlement Value
• Non-Opioid Pain Treatments 2026: PI Attorney Guide
• Tonmya for Post-Traumatic Fibromyalgia on Pharmacy Lien
• CGRP Medications: A Complete Guide for Personal Injury